RxDoctor Payments DataLook up a doctor →

Katherine Coleman, APRN

Family · Columbia, SCNPI 1659732667

Payments from drug & device makers

$14,857in general payments, 2019–2025

Across 659 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Medtronic$2K
  • Alnylam Pharmaceuticals Inc.$1K
  • Pfizer$581
  • AstraZeneca$579
  • Merck$541
  • plus $2K from 16 others

What the payments were for

  • Travel & lodging$2,01214%
  • Food & beverage$12,84486%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,857 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$7,865
Medicare patients
33
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis11$254,990
FarxigaDapagliflozin Propanediol74$54,882
EntrestoSacubitril/Valsartan42$35,430
JardianceEmpagliflozin34$32,643
Warfarin Sodium123$1,641
Potassium Chloride71$1,132
Pantoprazole Sodium90$994
Atorvastatin Calcium79$901
Amiodarone Hcl46$882
Bumetanide34$817
Valsartan35$481
Carvedilol56$477
Ropinirole Hcl11$443
Duloxetine Hcl12$410
Spironolactone58$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax$581$254,99011 claims
AstraZenecaFarxiga$579$54,88274 claims
NovartisEntresto$527$35,43042 claims
Boehringer IngelheimJardiance$381$32,64334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →